Campbell Bradley L
President and CEO
Campbell Bradley L has filed 7 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Apr 27, 2026.
On the most recent filing, Campbell Bradley L is listed as President and CEO at AMICUS THERAPEUTICS, INC. Inside the rolling window, Campbell Bradley L reported no open-market purchases and 5 open-market sales totaling $2.5M in FOLD. The largest disclosed transaction in the window is a sale of 75,000 FOLD shares on Jan 20, 2026, worth $1.1M.
Companies traded
Other insiders at FOLD
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.5M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Campbell Bradley L made?
Campbell Bradley L has filed 7 SEC Form 4 filings (11 transaction rows) across 1 company since 2025.
Which companies does Campbell Bradley L trade?
Campbell Bradley L has filed SEC Form 4 disclosures for 1 company, including FOLD.
When was Campbell Bradley L's most recent SEC Form 4 filing?
Campbell Bradley L's most recent SEC Form 4 filing on Tracefour is dated Apr 27, 2026.
What is Campbell Bradley L's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Campbell Bradley L is listed as President and CEO.
What is Campbell Bradley L's total buy and sell value in the current window?
Inside the rolling retention window, Campbell Bradley L bought $0 and sold $2.5M based on SEC Form 4 filings.
What was Campbell Bradley L's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 75,000 FOLD shares on 2026-01-20, worth $1.1M, per SEC Form 4 filings.